• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Ryan Jason

    10/19/21 7:24:24 PM ET
    $CMLF
    Business Services
    Finance
    Get the next $CMLF alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Ryan Jason

    (Last) (First) (Middle)
    C/O SEMA4 HOLDINGS CORP.
    333 LUDLOW ST, NORTH TOWER, 8TH FL.

    (Street)
    STAMFORD CT 06902

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Sema4 Holdings Corp. [ SMFR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    10/15/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (Right to Buy) $7.79 10/15/2021 A 22,286 (1) 10/14/2031 Class A Common Stock 22,286 $0.00 22,286 D
    Employee Stock Option (Right to Buy) $7.79 10/15/2021 A 22,286 (2) 10/14/2031 Class A Common Stock 22,286 $0.00 22,286 D
    Restricted Stock Unit (3) 10/15/2021 A 12,836 (1) (1) Class A Common Stock 12,836 $0.00 12,836 D
    Restricted Stock Unit (3) 10/15/2021 A 12,836 (4) (4) Class A Common Stock 12,836 $0.00 12,836 D
    Explanation of Responses:
    1. The stock options and restricted stock units ("RSUs") will vest on the earlier of (i) the date of the next annual meeting of the Issuer's shareholders following the grant date and (i) the first anniversary of the grant date, in each case so long as the Reporting Person continues to provide services to the Issuer through such vesting date.
    2. The stock option shall vest as of 1/36 of the total shares monthly beginning on November 15, 2021 until fully vested, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.
    3. Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
    4. The RSUs will vest in equal annual installments over the three-year period following the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.
    Remarks:
    /s/ Daniel Clark, Attorney-in-Fact 10/19/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CMLF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMLF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CMLF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

      37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiterating full year 2022 total revenue guidance of $215-225 million Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic and ope

      3/14/22 4:05:00 PM ET
      $CMLF
      $SMFR
      Business Services
      Finance
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company

      Sema4 Holdings Corp ("Sema4") to debut on Nasdaq as a publicly traded company dedicated to transforming healthcare by applying artificial intelligence and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human healthBusiness combination expected to result in ~$500 million in cash proceeds to Sema4 to accelerate organic and inorganic growthCombined company to trade on Nasdaq under ticker "SMFR" STAMFORD, Conn., July 22, 2021 (GLOBE NEWSWIRE) -- Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the completion of its business combination with CM Life

      7/22/21 9:15:41 AM ET
      $TWST
      $MGTA
      $CMLF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Business Services
    • Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors

      Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of renowned executive Jason Ryan to its Board of Directors. Mr. Ryan will begin serving on Sema4's Board of Directors upon his official appointment after Sema4 closes its previously announced business combination with CM Life Sciences (NASDAQ:CMLF), a special purpose acquisition company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005228/en/Jason Ryan (Photo: Business Wire) Mr. Ryan most recently served as Chief Operating and Financial Officer of Magenta Therapeutics (NA

      7/7/21 7:00:00 AM ET
      $TWST
      $CMLF
      $MGTA
      $OMIC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Business Services
      Finance

    $CMLF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by CM Life Sciences, Inc.

      SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

      10/13/21 2:31:34 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form SC 13D filed by CM Life Sciences, Inc.

      SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

      8/30/21 4:45:58 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form SC 13D filed by CM Life Sciences, Inc.

      SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)

      8/2/21 4:59:57 PM ET
      $CMLF
      Business Services
      Finance

    $CMLF
    Leadership Updates

    Live Leadership Updates

    See more
    • Sema4 Appoints Andrew Kasarskis, Health Data Expert and Precision Medicine Scientist, as Chief Data Officer

      Sema4, a patient-centered health intelligence company leveraging AI and machine learning to derive data-driven insights, today announced the appointment of Andrew Kasarskis, PhD, to the newly established role of Chief Data Officer (CDO). Dr. Kasarskis brings more than 20 years of leadership and broad experience in industry and academia that includes a strong focus on digital analytics and genomics and internationally recognized research in the life sciences. At Sema4, he will be responsible for establishing additional structures and processes to further optimize the company's health intelligence platform and orchestrating data use and data science to support research, development, and innov

      6/17/21 7:00:00 AM ET
      $CMLF
      Business Services
      Finance

    $CMLF
    SEC Filings

    See more
    • SEC Form 424B3 filed by CM Life Sciences, Inc.

      424B3 - Sema4 Holdings Corp. (0001818331) (Filer)

      10/14/21 9:58:15 PM ET
      $CMLF
      Business Services
      Finance
    • CM Life Sciences, Inc. filed SEC Form 8-K: Leadership Update

      8-K - Sema4 Holdings Corp. (0001818331) (Filer)

      10/14/21 5:23:09 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form S-8 filed by CM Life Sciences, Inc.

      S-8 - Sema4 Holdings Corp. (0001818331) (Filer)

      9/27/21 4:46:23 PM ET
      $CMLF
      Business Services
      Finance

    $CMLF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Sherman Rachel E.

      4 - Sema4 Holdings Corp. (0001818331) (Issuer)

      10/19/21 7:31:01 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form 4 filed by Turner Nat

      4 - Sema4 Holdings Corp. (0001818331) (Issuer)

      10/19/21 7:29:25 PM ET
      $CMLF
      Business Services
      Finance
    • SEC Form 4 filed by Pellini Michael J

      4 - Sema4 Holdings Corp. (0001818331) (Issuer)

      10/19/21 7:27:37 PM ET
      $CMLF
      Business Services
      Finance

    $CMLF
    Financials

    Live finance-specific insights

    See more
    • Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

      37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiterating full year 2022 total revenue guidance of $215-225 million Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic and ope

      3/14/22 4:05:00 PM ET
      $CMLF
      $SMFR
      Business Services
      Finance
      Retail: Computer Software & Peripheral Equipment
      Technology